ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Galecto Inc

Galecto Inc (GLTO)

4.66
-0.13
(-2.71%)
마감 20 12월 6:00AM
4.81
0.15
(3.22%)
시간외 거래: 9:36AM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
4.81
매수가
4.33
매도가
22.10
거래량
42,953
4.4006 일간 변동폭 5.0821
4.66 52주 범위 23.50
market_cap
전일 종가
4.79
개장가
4.88
최근 거래 시간
16
@
4.99
마지막 거래 시간
재정 규모
US$ 201,206
VWAP
4.6843
평균 볼륨(3m)
25,720
발행 주식
1,316,989
배당수익률
-
주가수익률
-0.16
주당순이익(EPS)
-29.12
매출
-
순이익
-38.35M

Galecto Inc 정보

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Galecto Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker GLTO. The last closing price for Galecto was US$4.79. Over the last year, Galecto shares have traded in a share price range of US$ 4.66 to US$ 23.50.

Galecto currently has 1,316,989 shares in issue. The market capitalisation of Galecto is US$6.31 million. Galecto has a price to earnings ratio (PE ratio) of -0.16.

GLTO 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.54-10.09345794395.355.53844.66184815.14691441CS
4-1.04-17.77777777785.856.194.66196435.50465985CS
12-6.79-58.534482758611.612.44.66257207.28094033CS
26-7.4725-60.83859149212.282516.06754.6612989212.23153519CS
52-10.69-68.967741935515.523.54.6620340815.53164965CS
156-62.44-92.847583643167.2592.54.6618486927.98240297CS
260-389.44-98.7799619531394.25449.754.6622692375.52919736CS

GLTO - Frequently Asked Questions (FAQ)

What is the current Galecto share price?
The current share price of Galecto is US$ 4.81
How many Galecto shares are in issue?
Galecto has 1,316,989 shares in issue
What is the market cap of Galecto?
The market capitalisation of Galecto is USD 6.31M
What is the 1 year trading range for Galecto share price?
Galecto has traded in the range of US$ 4.66 to US$ 23.50 during the past year
What is the PE ratio of Galecto?
The price to earnings ratio of Galecto is -0.16
What is the reporting currency for Galecto?
Galecto reports financial results in USD
What is the latest annual profit for Galecto?
The latest annual profit of Galecto is USD -38.35M
What is the registered address of Galecto?
The registered address for Galecto is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Galecto website address?
The website address for Galecto is www.galecto.com
Which industry sector does Galecto operate in?
Galecto operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PRFXPainReform Ltd
US$ 11.08
(410.60%)
95.4M
NVNINVNI Group Ltd
US$ 2.66
(315.63%)
20.64M
BPTHBio Path Holdings Inc
US$ 1.50
(124.22%)
113.42M
ZCARZoomcar Holdings Inc
US$ 2.5999
(96.96%)
18.03M
APCXAppTech Payments Corporation
US$ 0.6203
(62.81%)
196.08M
LITMSnow Lake Resources Ltd
US$ 0.3025
(-63.09%)
72.24M
BSFCBlue Star Foods Corporation
US$ 0.1478
(-48.14%)
7.45M
QUBTQuantum Computing Inc
US$ 15.1396
(-41.05%)
122.47M
QMCOQuantum Corporation
US$ 36.02
(-39.99%)
7.07M
AEMDAethlon Medical Inc
US$ 0.4232
(-35.94%)
9.52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.561
(53.78%)
725.18M
NVDANVIDIA Corporation
US$ 130.68
(1.37%)
209.74M
APCXAppTech Payments Corporation
US$ 0.6203
(62.81%)
196.08M
RGTIRigetti Computing Inc
US$ 7.465
(-30.17%)
176.12M
SOUNSoundHound AI Inc
US$ 18.855
(-9.55%)
139.39M

GLTO Discussion

게시물 보기
Retire43 Retire43 2 월 전
GALT MENTIONED IN THIS ARTICLE.

https://www.zerohedge.com/news/2024-10-15/what-merck-doesnt-want-you-know-about-keytruda
👍️0
Retire43 Retire43 3 월 전
Please watch this and comment your opinion

👍️0
Monksdream Monksdream 3 월 전
GLTO under $15
👍️0
Retire43 Retire43 6 월 전
BIXT:

https://www.globenewswire.com/news-release/2024/06/27/2905450/0/en/Bioxytran-s-Advisor-Releases-Book-on-Hyperbaric-Oxygenation-Related-to-Stroke-Alzheimer-s-Patients.html
👍️0
Retire43 Retire43 7 월 전
Share this.


https://medicaldialogues.in/medicine/news/galectin-3-promising-biomarker-for-predicting-long-covid-among-patients-of-covid-19-study-129158
👍️0
Retire43 Retire43 7 월 전
Share this news with everyone, you know

https://www.insiderfinancial.com/post/playing-the-bird-flu-trade-cvac-bixt-nnvc-govx-dyai-nvax
👍️0
Retire43 Retire43 7 월 전
Todays emerging growth conference
CEO DAVID PLATT $BIXT
BioxyTran.

https://emerginggrowth.com/emerging-growth-conference-70/

👍️0
Retire43 Retire43 8 월 전
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
👍️0
Retire43 Retire43 1 년 전
https://www.zerohedge.com/news/2023-12-12/disease-x-resistance-futile
👍️0
TrendTrade2016 TrendTrade2016 1 년 전
glto on the move
👍️0
subslover subslover 1 년 전
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

As part of this evaluation process, Galecto will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, divestiture of its assets, technologies or capabilities, or other transaction. There can be no assurance that its exploration will result in Galecto pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.

In connection with the evaluation of strategic alternatives, Galecto plans to implement a restructuring plan that includes reducing its workforce by approximately 29 people, or approximately 70% of its existing headcount.

Galecto has not set a timetable for completion of the evaluation process and does not intend to disclose further developments or guidance on the status of its programs unless and until it is determined that further disclosure is appropriate or necessary.

As of June 30, 2023, Galecto’s cash, cash equivalents and investments balance was $52.1 million.
👍️0
Retire43 Retire43 1 년 전
Please share this!

https://x.com/MikeSheikh2/status/1704381059411169763?s=20
👍️0
Retire43 Retire43 1 년 전
Look at this Reprint. Share this !

https://www.preprints.org/manuscript/202309.0077/v1
👍️0
Retire43 Retire43 1 년 전
https://www.zerohedge.com/news/2023-09-12/mask-mandates-unpopular-due-existence-next-gen-antivirals-pipeline
👍️0
Retire43 Retire43 1 년 전
Did anyone catch this today ?

H.C. Wainwright 25th Annual Global Investment Conference

Date: Monday, September 11, 2023
Time: 7:00 am ET
Location: New York City, NY
👍️0
Butchmass Butchmass 1 년 전
When is this company going to start doing more to publicize itself. They could be more up front and active with the share holders.
👍️0
Triple nickle Triple nickle 1 년 전
Added a few down here
👍️0
Monksdream Monksdream 1 년 전
Damn shame
Sold quite a while ago at a profit
👍️0
TheFinalCD TheFinalCD 1 년 전
$GLTO (.80) -65% Galecto to discontinue development of lung disease treatment
Reuters
Tue, August 15, 2023 at 7:35 AM EDT

Aug 15 (Reuters) - Galecto Inc said on Tuesday it will dicontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)

https://finance.yahoo.com/news/galecto-discontinue-development-lung-disease-113556937.html
👍️0
Monksdream Monksdream 1 년 전
GLTO now ;No 11; on the Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 1 년 전
GLTO new 52/week high
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Butchmass Butchmass 1 년 전
Monksdream, I hope we see considerable more traffic on this board soon. Earnings coming out 7/28/2023.
👍️0
Monksdream Monksdream 1 년 전
GLTO No 3 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

최근 히스토리

Delayed Upgrade Clock